Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter and Randomized Controlled Trial to Evaluate the Efficacy and Safety of Sperstent® Peripheral Spot Stent System Used for the Residual Lesions After Percutaneous Transluminal Angioplasty of Femoropopliteal Arteries

NCT06539689 is registered in ClinicalTrials.gov with FrontAce Scientific Co., Ltd as lead sponsor.

NCT NCT06539689
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06539689 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter and Randomized Controlled Trial to Evaluate the Efficacy and Safety of Sperstent® Peripheral Spot Stent System Used for the Residual Lesions After Percutaneous Transluminal Angioplasty of Femoropopliteal Arteries
Lead sponsor
FrontAce Scientific Co., Ltd
Phase
Not applicable
Overall status
Recruiting
Start date
June 4, 2024
Completion date
December 31, 2026
Enrollment
240 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

dissection, peripheral arterial disease, stenosis